aTyr Pharma, Inc. (ATYR)
Automate Your Wheel Strategy on ATYR
With Tiblio's Option Bot, you can configure your own wheel strategy including ATYR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATYR
- Rev/Share 0.0
- Book/Share 0.8284
- PB 1.1635
- Debt/Equity 0.1694
- CurrentRatio 5.6334
- ROIC -0.8021
- MktCap 94684484.0
- FreeCF/Share -0.6175
- PFCF -1.7013
- PE -1.3068
- Debt/Assets 0.1249
- DivYield 0
- ROE -0.9345
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ATYR | RBC Capital Mkts | Outperform | Sector Perform | -- | $1.5 | Sept. 16, 2025 |
| Downgrade | ATYR | Leerink Partners | Outperform | Market Perform | -- | $1 | Sept. 15, 2025 |
| Downgrade | ATYR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | H.C. Wainwright | Buy | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | Wells Fargo | Overweight | Equal Weight | -- | $1 | Sept. 15, 2025 |
| Initiation | ATYR | Leerink Partners | -- | Outperform | -- | $16 | Feb. 18, 2025 |
| Initiation | ATYR | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 6, 2025 |
| Initiation | ATYR | Wells Fargo | -- | Overweight | -- | $17 | Oct. 4, 2024 |
| Initiation | ATYR | Jefferies | -- | Buy | -- | $9 | Sept. 5, 2024 |
News
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: October 23, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO.
Read More
ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors
Published: October 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the "Company") (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
Read More
Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between January 16, 2025 and September 12, 2025.
Read More
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Oct. 21, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ATYR
Published: October 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Law Offices of Frank R. Cruz Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
Published: October 17, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action.
Read More
Law Offices of Howard G. Smith Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
Published: October 17, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO P.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
Published: October 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
Published: October 17, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Oct. 17, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims.
Read More
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
Published: October 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims.
Read More
Securities Fraud Investigation Into aTyr Pharma Inc. (ATYR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Published: October 16, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATYR PHARMA INC. (ATYR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On September 15,.
Read More
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Published: October 16, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at h.
Read More
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors
Published: October 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the "Company") (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
Read More
Faruqi & Faruqi Reminds ATyr Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 9, 2025 - ATYR
Published: October 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ATyr To Contact Him Directly To Discuss Their Options
Read More
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
Published: October 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025.
Read More
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
Published: October 15, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims. Blog: www.hbsslaw.com/blog The firm urges investors in aTyr who suffered significant losses to submit your losses now. The.
Read More
ATYR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: October 15, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired aTyr securities between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period").
Read More
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
Published: October 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial.
Read More
Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: October 10, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). aTyr is a clinical stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is I.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: October 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
Read More
aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline Alert: Shamis & Gentile, P.A. Alerts Investors of Important Lead Plaintiff Deadline of December 8, 2025
Published: October 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Shamis & Gentile, P.A. alerts investors that a securities class action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) on behalf of investors who purchased or otherwise acquired aTyr Pharma common stock between January 16, 2025 and September 12, 2025, inclusive.
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: October 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal.
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal. The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether aTyr may have misled investors about the Phase 2 data and its Phase 3 EFZO-FIT trial design.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
Published: October 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal.
Read More
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal.
Read More
About aTyr Pharma, Inc. (ATYR)
- IPO Date
- Website https://www.atyrpharma.com
- Industry Biotechnology
- CEO Sanjay S. Shukla
- Employees 56